Hepatitis b immunisation regimen and compositions
AssigneeGlaxosmithkline Biologicals SA
InventorsVirginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI
Life of this patent
Estimating the term…
Loading patent…
AssigneeGlaxosmithkline Biologicals SA
InventorsVirginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI
Estimating the term…
There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
A method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of:
A method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of:
A method of treating chronic hepatitis B infection (CHB) in a human with an immunogenic composition, the immunogenic combination comprising:
A method of treating chronic hepatitis B infection (CHB) in a human with an immunogenic composition, the immunogenic composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs), a nucleic acid encoding a hepatitis B virus core antigen (HBc) and a nucleic acid encoding the human invariant chain (hIi) fused to the HBc, wherein the method comprises administering the composition in a prime-boost regimen with at least one other immunogenic composition.
A method of treating or preventing chronic hepatitis B infection in a human with an immunogenic composition, where the immunogenic composition comprises a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc)-wherein the method comprises administering the immunogenic composition in a prime-boost regimen with at least one other immunogenic composition.
A method of treating chronic hepatitis B infection (CHB) in a human with an immunogenic composition, the immunogenic composition comprising a recombinant hepatitis B surface antigen (HBs), a C-terminal truncated recombinant hepatitis B virus core antigen (HBc) and an adjuvant containing MPL and QS-21, wherein the method comprises administering the composition in a prime-boost regimen with at least one other immunogenic composition.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.